<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0075">
 <label>75.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Arabi</surname>
    <given-names>YM</given-names>
   </name>, 
   <name name-style="western">
    <surname>Alothman</surname>
    <given-names>A</given-names>
   </name>, 
   <name name-style="western">
    <surname>Balkhy</surname>
    <given-names>HH</given-names>
   </name>, 
   <name name-style="western">
    <surname>Al-Dawood</surname>
    <given-names>A</given-names>
   </name>, 
   <name name-style="western">
    <surname>AlJohani</surname>
    <given-names>S</given-names>
   </name>, 
   <name name-style="western">
    <surname>Al Harbi</surname>
    <given-names>S</given-names>
   </name>, 
   <name name-style="western">
    <surname>Kojan</surname>
    <given-names>S</given-names>
   </name>, 
   <name name-style="western">
    <surname>Al Jeraisy</surname>
    <given-names>M</given-names>
   </name>, 
   <name name-style="western">
    <surname>Deeb</surname>
    <given-names>AM</given-names>
   </name>, 
   <name name-style="western">
    <surname>Assiri</surname>
    <given-names>AM</given-names>
   </name>, et al.; 
   <collab>And the MIRACLE trial group</collab>
  </person-group>
  <article-title>Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-Î²1b (MIRACLE trial): study protocol for a randomized controlled trial</article-title>. 
  <source>Trials</source>. 
  <year>2018</year>;
  <volume>19</volume>(
  <issue>1</issue>):
  <fpage>81</fpage>. doi:
  <pub-id pub-id-type="doi">10.1186/s13063-017-2427-0</pub-id>.
  <pub-id pub-id-type="pmid">29382391</pub-id>
 </mixed-citation>
</ref>
